This slideshow reviews talimogene laherparepvec (Imlygic), indicated for unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma after initial surgery/ Table of Contents Slide 4: Dosage and AdministrationSlide 11: Cautions, Effects, and InteractionsSlide 18: What to Tell Your PatientSlide 26: Reference
This slideshow reviews belinostat (Beleodaq), indicated for relapsed or refractory peripheral T-cell lymphoma (PTCL). Table of Contents Slide 4: Dosage and AdministrationSlide 12: Cautions, Effects, and InteractionsSlide 18: What to Tell Your PatientSlide 24: Reference
This slideshow reviews osimertinib (Tagrisso), indicated for HFirst-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations. Table of Contents Slide 4: Dosage and AdministrationSlide 14: Cautions, Effects, and InteractionsSlide 22: What to Tell Your PatientSlide 29: Reference
This slideshow reviews palbociclib (Ibrance), indicated for Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer . Table of Contents Slide 4: Dosage and AdministrationSlide 14: Cautions, Effects, and InteractionsSlide 19: What to Tell Your PatientSlide 24: Reference
This slideshow reviews ceritinib (Zykadia), indicated for metastatic non-small cell lung cancer (NSCLC) in patients with ALK-positive tumors. Table of Contents Slide 4: Dosage and AdministrationSlide 15: Cautions, Effects, and InteractionsSlide 23: What to Tell Your PatientSlide 32: Reference
This slideshow reviews ruxolitinib (Jakafi), indicated for intermediate or high-risk myelofibrosis, and polycythemia vera in cases of inadequate response or intolerance of hydroxyurea. Table of Contents Slide 4: Dosage and AdministrationSlide 17: Cautions, Effects, and InteractionsSlide 24: What to Tell Your PatientSlide 29: Reference
This slideshow reviews acalabrutinib (Calquence), indicated for the treatment of myelodysplastic syndrome (MDS). Table of Contents Slide 4: Dosage and AdministrationSlide 11: Cautions, Effects, and InteractionsSlide 17: What to Tell Your PatientSlide 23: Reference
This slideshow reviews decitabine (Dacogen), indicated for the treatment of myelodysplastic syndrome (MDS). Table of Contents Slide 5: Dosage and AdministrationSlide 14: Cautions, Effects, and InteractionsSlide 19: What to Tell Your PatientSlide 24: Reference
This slideshow reviews ibrutinib (Imbruvica), indicated for the treatment of certain leukemias and lymphomas and chronic graft versus host disease (cGVHD) in adult patients. Table of Contents Slide 5: Dosage and AdministrationSlide 15: Cautions, Effects, and InteractionsSlide 24: What to Tell Your PatientSlide 32: Reference
This slideshow reviews ipilimumab (Yervoy), for the treatment of unresectable or metastatic melanoma. Table of Contents Slide 4: Dosage and AdministrationSlide 8: Cautions, Effects, and InteractionsSlide 16: What to Tell Your PatientSlide 22: References
